Shattuck Labs (NASDAQ:STTK) vs. Celldex Therapeutics (NASDAQ:CLDX) Head to Head Review

Celldex Therapeutics (NASDAQ:CLDX) and Shattuck Labs (NASDAQ:STTK) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, risk, dividends, institutional ownership and profitability.

Institutional and Insider Ownership

58.7% of Shattuck Labs shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 8.8% of Shattuck Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and price targets for Celldex Therapeutics and Shattuck Labs, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1	1	11	0	2.77
Shattuck Labs	1	0	9	3	3.08

Celldex Therapeutics currently has a consensus price target of $63.08, suggesting a potential upside of 109.23%. Shattuck Labs has a consensus price target of $13.70, suggesting a potential upside of 137.44%. Given Shattuck Labs’ stronger consensus rating and higher probable upside, analysts plainly believe Shattuck Labs is more favorable than Celldex Therapeutics.

Profitability

This table compares Celldex Therapeutics and Shattuck Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	N/A	N/A
Shattuck Labs	N/A	N/A	N/A

Earnings and Valuation

This table compares Celldex Therapeutics and Shattuck Labs”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	N/A	N/A	N/A	($4.35)	-6.93
Shattuck Labs	N/A	N/A	N/A	($0.51)	-11.31

Shattuck Labs is trading at a lower price-to-earnings ratio than Celldex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Shattuck Labs beats Celldex Therapeutics on 6 of the 7 factors compared between the two stocks.

About Celldex Therapeutics

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company’s clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

About Shattuck Labs

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.